Use QbD to Get Through Rough Patch, FDA Tells Transdermal Makers
This article was originally published in The Gold Sheet
Executive Summary
FDA officials say that there are “scientific gaps” in how transdermal patches are developed, manufactured and regulated, and urged manufacturers to adopt quality- by-design methods to help bridge these gaps and to better ensure product quality and safety.
You may also be interested in...
US FDA Suggests Using ICH Drug Guidance To Meet Device Quality Requirements for Transdermals
FDA’s draft guidance on transdermal and topical delivery systems says manufacturers can leverage pharmaceutical development studies principles for device design control requirements.
Drug Patch Manufacturers Can Skip Quality By Design Approach, FDA Says
Final guidance softens a recommendation that manufacturers of transdermal and transmucosal drug delivery systems and topical patches use a Quality by Design approach.
In Brief
FDA releases drug patch guidance